UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 25, 2020
BIO-key International, Inc.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation) | 1-13463 (Commission File Number) | 41-1741861 (I.R.S. Employer Identification No.) |
3349 Highway 138, Building A, Suite E
Wall, NJ 07719
(Address of principal executive offices)
(732) 359-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock | BKYI | Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
| | Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 25, 2020, the Compensation Committee of the Board of Directors of BIO-key International, Inc. (the “Company”) approved an issuance of restricted shares of common stock to Michael DePasquale, our Chief Executive Officer, to Cecilia Welch, our Chief Financial Officer, and to Mira LaCous, our Chief Technology Officer as follows:
Named Executive Officer | | Number of Restricted Shares |
Michael DePasquale | | 33,000 |
Cecilia Welch | | 33,000 |
Mira LaCous | | 33,000 |
The restricted shares of common stock were issued under the Company’s Amended & Restated 2015 Equity Incentive Plan and are subject to forfeiture if the grantee does not remain in continuous employment or service with the Company for a period of three (3) years from the date of the grant. The foregoing restrictions lapse in equal annual installments over such three (3) year period.
Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibit.
(d) Exhibits. The following exhibit is filed herewith:
10.1 Form of Restricted Stock Award Agreement under the BIO-key International, Inc. Amended & Restated 2015 Equity Incentive Plan
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIO-KEY INTERNATIONAL, INC. | |
Date: August 28, 2020 | | | |
| By: | /s/ Cecilia C. Welch | |
| | Cecilia C. Welch | |
| | Chief Financial Officer | |
